ENTA Stock Overview
A biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Enanta Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.81 |
| 52 Week High | US$17.24 |
| 52 Week Low | US$4.09 |
| Beta | 0.82 |
| 1 Month Change | 3.75% |
| 3 Month Change | -27.65% |
| 1 Year Change | -51.70% |
| 3 Year Change | -85.28% |
| 5 Year Change | -88.72% |
| Change since IPO | -66.18% |
Recent News & Updates
Recent updates
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 18
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Not Doing Enough For Some Investors As Its Shares Slump 27%
Mar 31Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Shares Bounce 55% But Its Business Still Trails The Industry
Feb 14Analysts Have Been Trimming Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target After Its Latest Report
Nov 30Benign Growth For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Underpins Stock's 27% Plummet
Nov 27Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?
Oct 05Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results
Aug 08Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%
Jul 24Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?
Jun 19Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
May 09Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth
Mar 05Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 12Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook
Aug 13We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed
Feb 24Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade
Feb 08Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term
Nov 25Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?
Oct 25Enanta starts mid-stage trial of EDP-938 for RSV infection
Oct 03Enanta Pharma FQ3 2022 Earnings Preview
Aug 07Enanta potential COVID drug shows safety in healthy people in early-stage trial
Jul 29Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?
Jul 04Enanta: Slow Drip
May 17Shareholder Returns
| ENTA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.0% | 1.0% | -2.7% |
| 1Y | -51.7% | -13.2% | 9.0% |
Return vs Industry: ENTA underperformed the US Biotechs industry which returned -13% over the past year.
Return vs Market: ENTA underperformed the US Market which returned 10.5% over the past year.
Price Volatility
| ENTA volatility | |
|---|---|
| ENTA Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: ENTA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ENTA's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 131 | Jay Luly | www.enanta.com |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir.
Enanta Pharmaceuticals, Inc. Fundamentals Summary
| ENTA fundamental statistics | |
|---|---|
| Market cap | US$122.92m |
| Earnings (TTM) | -US$96.41m |
| Revenue (TTM) | US$64.46m |
Is ENTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENTA income statement (TTM) | |
|---|---|
| Revenue | US$64.46m |
| Cost of Revenue | US$0 |
| Gross Profit | US$64.46m |
| Other Expenses | US$160.88m |
| Earnings | -US$96.41m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 11, 2025
| Earnings per share (EPS) | -4.51 |
| Gross Margin | 100.00% |
| Net Profit Margin | -149.57% |
| Debt/Equity Ratio | 168.3% |
How did ENTA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 03:32 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Enanta Pharmaceuticals, Inc. is covered by 19 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Geoffrey Meacham | Barclays |
| Patrick Trucchio | Berenberg |